ES8707766A1 - Procedimiento para la obtencion de compuestos de desulfatohirudina - Google Patents

Procedimiento para la obtencion de compuestos de desulfatohirudina

Info

Publication number
ES8707766A1
ES8707766A1 ES557116A ES557116A ES8707766A1 ES 8707766 A1 ES8707766 A1 ES 8707766A1 ES 557116 A ES557116 A ES 557116A ES 557116 A ES557116 A ES 557116A ES 8707766 A1 ES8707766 A1 ES 8707766A1
Authority
ES
Spain
Prior art keywords
host cells
dna sequences
hybrid vectors
thrombin
thrombin inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES557116A
Other languages
English (en)
Other versions
ES557116A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES557116A0 publication Critical patent/ES557116A0/es
Publication of ES8707766A1 publication Critical patent/ES8707766A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METODO DE OBTENER COMPUESTOS DE DESULFATOHIRUDINA. COMPRENDE: A) CULTIVAR CELULAS ANFITRIONES TRANSFORMADAS CON UN VECTOR DE EXPRESION EN UN MEDIO NUTRIENTE LIQUIDO, PARA FORMAR COMPUESTOS DE FORMULA (I); LIBERAR EL COMPUESTO DE FORMULA (I) DE LA CELULA ANFITRION; Y C) AISLAR EL COMPUESTO DE FORMULA (I) POR CROMATOGRAFIA. EL VECTOR DE EXPRESION CONTIENE UNA SECUENCIA DNA REGULADA POR UNA SECUENCIA DE CONTROL DE EXPRESION CODIFICADORA DE LA SECUENCIA AMINOACIDO DE HIRUDINA Y EL MEDIO NUTRIENTE CONTIENE FUENTES DE C Y DE N, SIENDO V VAL Y W TYR. SE UTILIZAN COMO ANTITROMBOTICOS.
ES557116A 1984-06-14 1986-10-01 Procedimiento para la obtencion de compuestos de desulfatohirudina Expired ES8707766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH288284 1984-06-14

Publications (2)

Publication Number Publication Date
ES557116A0 ES557116A0 (es) 1987-08-16
ES8707766A1 true ES8707766A1 (es) 1987-08-16

Family

ID=4243708

Family Applications (3)

Application Number Title Priority Date Filing Date
ES544126A Expired ES8708012A1 (es) 1984-06-14 1985-06-13 Procedimiento para la obtencion de secuencias de dna
ES557115A Expired ES8707765A1 (es) 1984-06-14 1986-10-01 Procedimiento para la obtencion de vectores d hibridos
ES557116A Expired ES8707766A1 (es) 1984-06-14 1986-10-01 Procedimiento para la obtencion de compuestos de desulfatohirudina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES544126A Expired ES8708012A1 (es) 1984-06-14 1985-06-13 Procedimiento para la obtencion de secuencias de dna
ES557115A Expired ES8707765A1 (es) 1984-06-14 1986-10-01 Procedimiento para la obtencion de vectores d hibridos

Country Status (23)

Country Link
US (2) US5422249A (es)
EP (1) EP0168342B1 (es)
JP (1) JPH0720434B2 (es)
KR (1) KR920009522B1 (es)
AT (1) ATE64956T1 (es)
AU (1) AU591061B2 (es)
CA (1) CA1341426C (es)
CY (1) CY1782A (es)
DD (1) DD240392A5 (es)
DE (1) DE3583361D1 (es)
DK (1) DK175496B1 (es)
ES (3) ES8708012A1 (es)
FI (1) FI90787C (es)
GR (1) GR851428B (es)
HK (1) HK11095A (es)
HU (1) HU202288B (es)
IE (1) IE57999B1 (es)
IL (1) IL75508A (es)
NO (2) NO177433C (es)
NZ (1) NZ212405A (es)
PH (1) PH26867A (es)
PT (1) PT80631B (es)
ZA (1) ZA854418B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
US5705355A (en) * 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3445517C2 (de) * 1984-12-13 1993-11-18 Ciba Geigy Für ein Hirudin-ähnliches Protein codierende DNA-Sequenz und Verfahren zur Herstellung eines Hirudin-ähnlichen Proteins
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
US5821079A (en) * 1985-05-02 1998-10-13 Transgene S.A. Vectors for the expression and secretion of hirudin by transformed yeasts
GB8530631D0 (en) 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
MY101203A (en) * 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
FR2607516B2 (fr) * 1986-12-01 1989-12-22 Transgene Sa Vecteurs perfectionnes d'expression d'un variant de l'hirudine dans les levures, procede et produit obtenu
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
FR2607517B2 (fr) * 1986-12-01 1989-12-22 Transgene Sa Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu
US5256559A (en) * 1988-03-04 1993-10-26 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
GB8817161D0 (en) * 1988-07-19 1988-08-24 Ciba Geigy Ag Modified proteins
GB8817160D0 (en) * 1988-07-19 1988-08-24 Ciba Geigy Ag Novel proteins
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
DE3835815A1 (de) * 1988-10-21 1990-04-26 Hoechst Ag Neue isohirudine
ATE119195T1 (de) * 1989-01-25 1995-03-15 Ciba Geigy Ag Monoklonale antikörper, spezifisch für hirudin.
DE69028725T2 (de) * 1989-02-28 1997-03-13 Canon Kk Partiell doppelsträngiges Oligonukleotid und Verfahren zu seiner Bildung
JPH037583A (ja) * 1989-02-28 1991-01-14 Canon Inc 部分的二本鎖オリゴヌクレオチド及びオリゴヌクレオチドの形成方法
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
US6060451A (en) * 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5296352A (en) * 1990-10-02 1994-03-22 Ciba-Geigy Corporation Monoclonal antibodies directed against complexes formed by thrombin and hirudin
US6514730B1 (en) 1991-03-21 2003-02-04 Consortium für elektrochemische Industrie GmbH Secretion of hirudin derivatives
DE4209110A1 (de) * 1991-11-26 1993-05-27 Basf Ag Neue thrombininhibitorische proteine aus landblutegeln
DE4140381A1 (de) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De Neue synthetische isohirudine mit verbesserter stabilitaet
HU214698B (hu) * 1992-04-09 1998-06-29 Gyógyszerkutató Intézet Kft. Eljárás rekombináns deszulfátó-hirudin HV-1 peptidek előállítására
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
US5643580A (en) * 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
DE19529997C1 (de) * 1995-08-16 1997-04-10 Hoechst Ag Verfahren zur Inaktivierung von Carboxypeptidase Y in hirudinhaltigen Kulturbrühen
DE19543737A1 (de) * 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
DE19544233A1 (de) 1995-11-28 1997-06-05 Hoechst Ag Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
DE69625623T2 (de) 1996-01-31 2003-11-06 Sumitomo Bakelite Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von in Epoxyharz eingekapselter Halbleitervorrichtung
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
DE10149678A1 (de) 2001-10-09 2009-03-12 Novel Science International Gmbh Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung
US20070016969A1 (en) * 2002-01-18 2007-01-18 Animal Technology Institute Taiwan Expression vector for hirudin and transformed cells and transgenic animals containing said vector
DE10301255A1 (de) 2003-01-15 2004-07-29 Cpi Creative Pharma International Gmbh Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung
JP3535151B1 (ja) * 2003-07-10 2004-06-07 株式会社ミナキアドバンス 生酵母菌を成分とする液剤の製造方法及びその液剤
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
BRPI0821599A2 (pt) * 2007-12-28 2015-06-16 Baxter Int Método de filtração de uma mistura líquida de proteína

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432596A (en) * 1967-10-13 1969-03-11 Dresden Arzneimittel Method for producing highly pure hirudine
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4517294A (en) * 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
GR79124B (es) * 1982-12-22 1984-10-02 Genentech Inc
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DE3342139A1 (de) * 1983-11-22 1985-05-30 Ciba-Geigy Ag, Basel Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
FR2562088B1 (fr) * 1984-03-27 1987-11-13 Transgene Sa Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
DE3689525D1 (de) * 1985-07-17 1994-02-24 Hoechst Ag Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel.
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
MY101203A (en) * 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
FR2645175B1 (fr) * 1989-03-31 1994-02-18 Transgene Sa Souche de saccharomyces cerevisiaeproductrice d'une proteine heterologue et procede de preparation de ladite proteine heterologue par fermentation de ladite souche

Also Published As

Publication number Publication date
DE3583361D1 (de) 1991-08-08
AU4365585A (en) 1985-12-19
ES8708012A1 (es) 1987-09-01
EP0168342B1 (de) 1991-07-03
FI90787B (fi) 1993-12-15
IL75508A (en) 1991-06-10
HU202288B (en) 1991-02-28
IE57999B1 (en) 1993-06-02
GR851428B (es) 1985-11-25
NO177433B (no) 1995-06-06
AU591061B2 (en) 1989-11-30
CY1782A (en) 1995-10-20
KR860000381A (ko) 1986-01-28
PT80631B (de) 1987-04-28
DK175496B1 (da) 2004-11-08
HK11095A (en) 1995-02-03
NZ212405A (en) 1989-01-06
JPH0720434B2 (ja) 1995-03-08
NO177433C (no) 1995-09-13
ES8707765A1 (es) 1987-08-16
ES557116A0 (es) 1987-08-16
DK265685A (da) 1985-12-15
FI90787C (fi) 1994-03-25
IE851475L (en) 1985-12-14
CA1341426C (en) 2003-04-01
DK265685D0 (da) 1985-06-13
HUT38674A (en) 1986-06-30
JPS6119492A (ja) 1986-01-28
NO852389L (no) 1985-12-16
NO1999023I1 (no) 1999-11-17
PT80631A (de) 1985-07-01
IL75508A0 (en) 1985-10-31
KR920009522B1 (ko) 1992-10-17
PH26867A (en) 1992-11-16
ES544126A0 (es) 1987-09-01
ZA854418B (en) 1986-02-26
DD240392A5 (de) 1986-10-29
ATE64956T1 (de) 1991-07-15
FI852342A0 (fi) 1985-06-12
ES557115A0 (es) 1987-08-16
EP0168342A1 (de) 1986-01-15
FI852342L (fi) 1985-12-15
US5728549A (en) 1998-03-17
US5422249A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
ES8707765A1 (es) Procedimiento para la obtencion de vectores d hibridos
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
ES2000852A6 (es) Un nuevo procedimiento para preparar intermediarios con residuos de acido 5-amino-2,5-disustituido -4- hidroxipentanoico,utiles en la sintesis de polipeptidos inhibidores de renina.
UA32548C2 (uk) Ізольована послідовність днк, що кодує epsps фермент, ізольована послідовність днк, що кодує білок, який виявляє epsps активність, рекомбінантна двониткова молекула днк, спосіб одержання генетично трансформованих рослин
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
EP0305488A4 (en) Mycobacterial recombinants and peptides
CA2085881A1 (en) Dna encoding mammalian phosphodiesterases
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
AU692988B2 (en) Superior thrombomodulin analogs for pharmaceutical use

Legal Events

Date Code Title Description
PC1A Transfer granted
SPCF Request for supplementary protection certificate filed

Free format text: DESIRUDIN (REVASC)

Spc suppl protection certif: C9800001

Filing date: 19980107

SPCG Supplementary protection certificate granted

Free format text: DESIRUDIN (REVASC)

Spc suppl protection certif: C9800001

Filing date: 19980107

Expiry date: 20120610

FD1A Patent lapsed

Effective date: 20100528